Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Memorial Sloan Kettering Cancer Center · University of Pavia · +37 more institutions
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus…
Citation impact
- FWCI
- 55.32
- Percentile
- 100%
- References
- 7
Authors
241Topics & keywords
- Medicine
- Lenvatinib
- Sunitinib
- Clinical endpoint
- Renal cell carcinoma
- Internal medicine
- Hazard ratio
- Pembrolizumab
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizerAward: P30 CA008748
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- MSMemorial Sloan-Kettering Cancer CenterAward: CA008748
- EExelixisAward: P30 CA008748
- TTTizona Therapeutics
- BBeiGene
- IIncyte
- AAAdvanced Accelerator Applications
- SSeagen
- EEisaiAward: P30 CA008748
- APAstellas Pharma
- OPOno Pharmaceutical
- IIpsen
- EPEUSA Pharma
- LCLG Chem
- GGenentechAward: P30 CA008748
- ESEMD Serono
- CPChugai Pharmaceutical
- DSDaiichi Sankyo Europe
- CCilag